Matthew S. Scarano

Cooley advised Autolus Therapeutics (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, on its strategic financing with Perceptive Advisors for the sale of notes of up to $250 million in aggregate principal amount in a five-year, interest-only senior credit facility, subject to certain conditions.

Cooley advised Procore Technologies, the leading global provider of construction management software, on its agreement to acquire DroneDeploy, the robotics and visual intelligence platform for the built world that is used on over 3 million jobsites across more than 180 countries. Procore will acquire DroneDeploy for approximately $845 million in cash, subject to customary purchase price adjustments.

Cooley advised Neurocrine (Nasdaq: NBIX), a leading biopharmaceutical company, on its $1 billion five-year revolving credit facility.

Cooley advised Core Scientific (Nasdaq: CORZ), a leader in digital infrastructure for high-density colocation, in connection with an offering of $3.3 billion aggregate principal amount of 7.750% senior secured notes due 2031 issued by its wholly-owned subsidiary, Core Scientific Finance I LLC, at an issue price equal to 99.250% of the principal amount thereof.

Cooley advised Neurocrine, a leading biopharmaceutical company, on its agreement to acquire Soleno, a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases, for $2.9 billion.